Fms样酪氨酸激酶3表达对评估急性髓系白血病预后的意义  

The clinical significance of fms.like tyrosine kinase3 expression for evaluating the prognosis of acute myeloid leukemia

作　　者：庞丽萍[1] 陈甜甜[2] 徐海婵[1] 许蕾[1] 冯佳[1] 张文丽[1] 钟风鸾[1] 孟庆祥[1] 

机构地区：[1]北京大学深圳医院血液科,广东省深圳518036 [2]深圳市中医院检验科

出　　处：《中国基层医药》2012年第10期1462-1463,共2页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的探讨Fms样酪氨酸激酶3（FLT3）表达对评估急性髓系白血病（AML）预后的意义。方法选取AML患者50例，其中核型正常的AML患者20例，核型异常的AML患者30例。分别于化疗前抽取骨髓3ml，用PCR方法检测白血病细胞FLT3的表达情况。结果核型正常的AMLFLT3的表达率为5．0％，核型异常的AMLFLT3的表达率为26．7％。难治复发的AMLFLT3的表达率是33．3％，持续完全缓解的AMLFLT3的表达率是4．5％。FLT3的表达情况与骨髓中高白血病细胞所占比例和高外周血白细胞计数有关，与FAB亚型无关。有FLT3表达的AML患者无病生存（DFS）和总体生存（OS）时间短，无FLT3表达的AML患者DFS和OS时间长，二者差异有统计学意义（x2=4．17，P〈0．05）。结论FLT3是AML患者预后不好的因素，可以指导临床个体化治疗AML。Objective To explore the clinical significance of fms-like tyrosine kinase3 （FLT3） expression in evaluation prognosis of acute myeloid leukemia （AML） prognosis. Methods 50 patients with AML were selected. AML patients with normal karyotype were 20 cases, the abnormal karyotype were 30 cases. 3ml bone marrow before themotherapy was aspirated respectively, and the FLT3 gene expression in leukemia cells was detected with polyenzyme chain react（PCR）. Results The FLT3 expression rate in AML patients with normal karyotype was 5.0% , and was 26.7 % in AML patients with abnormal karyotype, 33.3 % in AML patients with refractory-relapse, and 4.5 % in AML patients with continue remission. The FLT3 expression rate was related with high leukemia cells percentage in bone marrow and high blood cells count in peripheral blood, and was not related with Franch America British（FAB） classification. The free-disease survival （FDS） and overall survived （OS） was shorter in FLT3 expression AML patients than that in no FLT3 expression AML patients. There was a statistical significance between the former and the latter （x2 = 4.17, P 〈 0.05 ）. Conclusion FLT3 was a kind of worse factor in AML patients prognosis, and could guide clinical individual treatment in AML.

关 键 词：白血病 急性 髓系 酪氨酸激酶 预后 

分 类 号：R733.71[医药卫生—肿瘤]